Protective and pathological roles of regulatory immune cells in human cytomegalovirus infection following hematopoietic stem cell transplantation.
HCMV
HSCT
MDSCs
regulatory T cells
Journal
Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
29
11
2021
received:
25
09
2021
accepted:
30
11
2021
pubmed:
17
12
2021
medline:
9
7
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
Human cytomegalovirus (HCMV) is ubiquitously prevalent. Immune system in healthy individuals is capable of controlling HCMV infection; however, HCMV can be life-threatening for immunocompromised individuals, such as transplant recipients. Both innate and adaptive immune systems are critically involved in the HCMV infection. Recent studies have indicated that regulatory immune cells which play essential roles in maintaining a healthy immune environment are closely related to immune response in HCMV infection. However, the exact role of regulatory immune cells in immune regulation and homoeostasis during the battle between HCMV and host still requires further research. In this review, we highlight the protective and pathological roles of regulatory immune cells in HCMV infection following hematopoietic stem cell transplantation (HSCT).
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2319Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102.
Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.
Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res. 2011;157(2):151-160.
Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41(3):180-185.
Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response. Front Cellular Infect Microbiol. 2020;10:130.
Seckert CK, Renzaho A, Reddehase MJ, Grzimek NK. Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection. Med Microbiol Immunol. 2008;197(2):251-259.
Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309-1314.
Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094-1097.
Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-e127.
Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 2018;7(1):1-16.
Takenaka K, Nishida T, Asano-Mori Y, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015;21(11):2008-2016.
Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood J Am Soc Hematol. 2016;127(20):2427-2438.
Stern L, Withers B, Avdic S, et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186.
Zhou X, Jin N, Chen B. Human cytomegalovirus infection: a considerable issue following allogeneic hematopoietic stem cell transplantation. Oncol Lett. 2021;21(4):1-15.
van der Heiden P, Marijt E, Falkenburg F, Jedema I. Control of cytomegalovirus viremia after allogeneic stem cell transplantation: a review on CMV-specific T cell reconstitution. Biol Blood Marrow Transplant. 2018;24(9):1776-1782.
Williams MA, Onami TM, Adams AB, et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol. 2002;169(10):5387-5391.
Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689-712.
Koehne G, Hasan A, Doubrovina E, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant. 2015;21(9):1663-1678.
Fuji S, Löffler J, Einsele H, Kapp M. Immunotherapy for opportunistic infections: current status and future perspectives. Virulence. 2016;7(8):939-949.
Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038-1044.
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238-241.
Guan Q, Xiao C, Zhang M. Immune regulatory cells in inflammation, infection, tumor, metabolism, and other diseases. Hindawi. 2018.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-787.
Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25+ CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162(9):5317-5326.
Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol. 2008;38(6):1654-1663.
Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol. 2013;4:152.
Ramlal R, Hildebrandt GC. Advances in the use of regulatory T-cells for the prevention and therapy of graft-vs.-host disease. Biomedicines. 2017;5(2):23.
Sun BL, Jain R, Patel C, Bhattacharyya AK. Graft-versus-host disease with early cytomegalovirus infection in gastrointestinal tract biopsies. Int J Surg Pathol. 2018;26(4):347-352.
Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78-83.
Özdemir E, St. John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood J Am Soc Hematol. 2002;100(10):3690-3697.
Morita-Hoshi Y, Heike Y, Kawakami M, et al. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(6):515-521.
Kuba A, Raida L. Graft versus host disease: from basic pathogenic principles to DNA damage response and cellular senescence. Mediat Inflamm. 2018;2018.
Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+ CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood J Am Soc Hematol. 2002;99(10):3493-3499.
Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+ CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Investig. 2003;112(11):1688-1696.
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+ CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
Edinger M, Hoffmann P, Ermann J, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
Pastore D, Delia M, Mestice A, et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(4):550-557.
Mizukawa Y, Kimishima M, Aoyama Y, Shiohara T. Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: a single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS). Int J Infect Dis. 2020;100:239-246.
Almanan M, Raynor J, Sholl A, et al. Tissue-specific control of latent CMV reactivation by regulatory T cells. PLoS Pathog. 2017;13(8):e1006507.
Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004;78(5):2454-2459.
Tovar-Salazar A, Weinberg A. Understanding the mechanism of action of cytomegalovirus-induced regulatory T cells. Virology. 2020;547:1-6.
Tovar-Salazar A, Patterson-Bartlett J, Jesser R, Weinberg A. Regulatory function of cytomegalovirus-specific CD4+ CD27− CD28− T cells. Virology. 2010;398(2):158-167.
Lyu M, Wang S, Gao K, Wang L, Li B, Tian L. Dissecting the landscape of activated CMV-stimulated CD4+ T cells in human by linking single-cell RNA-seq with T-cell receptor sequencing. bioRxiv. 2020.
Jesser RD, Li S, Weinberg A. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology. 2006;352(2):408-417.
Zhou Y. Regulatory T cells and viral infections. Front Biosci. 2008;13:1152-1170.
Broadley I, Pera A, Morrow G, Davies KA, Kern F. Expansions of cytotoxic CD4+ CD28− T cells drive excess cardiovascular mortality in rheumatoid arthritis and other chronic inflammatory conditions and are triggered by CMV infection. Front Immunol. 2017;8:195.
Ademe M. Paradoxes in the phenotype, frequency and roles of myeloid-derived suppressor cells during HIV infection. HIV/AIDS Auckl NZ). 2020;12:151-156.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
Köstlin N, Schoetensack C, Schwarz J, et al. Granulocytic myeloid-derived suppressor cells (GR-MDSC) in breast milk (BM); GR-MDSC accumulate in human BM and modulate T-cell and monocyte function. Front Immunol. 2018;9:1098.
Gimeno R, Barquinero J. Myeloid-derived suppressor cells (MDSC): another player in the orchestra. Inmunología. 2011;30(2):45-53.
Liu L, Lin Q, Peng J, et al Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response. EBioMedicine. 2020;60:103008.
Everts B, Amiel E, van der Windt GJ, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood J Am Soc Hematol. 2012;120(7):1422-1431.
Zhu D, Pan C, Sheng J, et al. Human cytomegalovirus reprogrammes haematopoietic progenitor cells into immunosuppressive monocytes to achieve latency. Nat Microbiol. 2018;3(4):503-513.
Mokry RL, Schumacher ML, Hogg N, Terhune SS. Nitric oxide circumvents virus-mediated metabolic regulation during human cytomegalovirus infection. mBio. 2020;11(6):e02630-20.
Smith MS, Bentz GL, Alexander JS, Yurochko AD. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol. 2004;78(9):4444-4453.
Reddy V, Meier-Kriesche H-U, Greene S, Schold JD, Wingard JR. Increased levels of tumor necrosis factor α are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(9):698-705.
Forghani P, Petersen CT, Waller EK. Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. Oncotarget. 2017;8(47):81873-81879.
Smalley S, Barrow P, Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol. 2009;157(2):225-234.
Buxbaum NP. We didn’t start the fire, MDSC inflammasome signaling in GVHD. Blood J Am Soc Hematol. 2019;134(19):1570-1572.
Park M-J, Baek J-A, Kim S-Y, et al. Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells. J Transl Med. 2020;18(1):1-14.
O'Connor MA, Rastad JL, Green WR. The role of myeloid-derived suppressor cells in viral infection. Viral Immunol. 2017;30(2):82-97.
Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M. The immunobiology of myeloid-derived suppressor cells in cancer. Tumor Biol. 2016;37(2):1387-1406.
Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B. Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol. 2012;188(9):4209-4216.
Srivastava MK, Zhu L, Harris-White M, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS one. 2012;7(7):e40677.
Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Hum Cytomegalovirus. 2008:417-470.
Medina E, Hartl D. Myeloid-derived suppressor cells in infection: a general overview. J Innate Immun. 2018;10(5-6):407-413.
Kruize Z, Kootstra NA. The role of macrophages in HIV-1 persistence and pathogenesis. Front Microbiol. 2019;10:2828.
Traylen CM, Patel HR, Fondaw W, et al. Virus reactivation: a panoramic view in human infections. Future Virol. 2011;6(4):451-463.
Sinzger C, Plachter B, Grefte A, The TH, Jahn G. Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dis. 1996;173(1):240-245.
Baasch S, Ruzsics Z, Henneke P. Cytomegaloviruses and macrophages-friends and foes from early on? Front Immunol. 2020;11:793.
Kulikauskaite J, Wack A. Teaching old dogs new tricks? The plasticity of lung alveolar macrophage subsets. Trends Immunol. 2020.
Min C-K, Shakya AK, Lee B-J, Streblow DN, Caposio P, Yurochko AD. The differentiation of human cytomegalovirus infected-monocytes is required for viral replication. Front Cell Infect Microbiol. 2020;10:368.
Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson J. Human cytomegalovirus productively infects primary differentiated macrophages. J Virol. 1991;65(12):6581-6588.
Bentz GL, Jarquin-Pardo M, Chan G, Smith MS, Sinzger C, Yurochko AD. HCMV infection of endothelial cells promotes naïve monocyte extravasation and the transfer of productive virus to enhance the hematogenous dissemination of HCMV. J Virol. 2006;80(23):11539-11555.
Chan G, Bivins-Smith ER, Smith MS, Smith PM, Yurochko AD. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol. 2008;181(1):698-711.
Cojohari O, Mahmud J, Altman AM, Peppenelli MA, Miller MJ, Chan GC. Human cytomegalovirus mediates unique monocyte-to-macrophage differentiation through the PI3K/SHIP1/Akt signaling network. Viruses. 2020;12(6):652.
Avdic S, Cao JZ, McSharry BP, et al. Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses. J Virol. 2013;87(18):10273-10282.
Michelson S, Alcami J, Kim S, et al. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol. 1994;68(9):5730-5737.
Fleming BD, Mosser DM. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol. 2011;41(9):2498-2502.
Broichhausen C, Riquelme P, Geissler EK, Hutchinson JA. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Curr Opin Organ Transplant. 2012;17(4):332-342.
Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol. 2011;187(5):2072-2078.
Hong Y-Q, Wan B, Li X-F. Macrophage regulation of graft-vs-host disease. World J Clin Cases. 2020;8(10):1793-1805.
Simorgh S, Milan PB, Saadatmand M, et al. Human olfactory mucosa stem cells delivery using a collagen hydrogel: as a potential Candidate for bone tissue Engineering. Materials. 2021;14(14):3909.
Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 2013;31:285-316.
Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229-2238.
Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2, 3-dioxygenase. Leukemia. 2011;25(4):648-654.
Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833.
Banani MA, Rahmatullah M, Farhan N, et al. Adipose tissue-derived mesenchymal stem cells for breast tissue regeneration. Regen Med. 2021;16(01):47-70.
Ge W, Jiang J, Baroja M, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9(8):1760-1772.
Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes. 2009;58(8):1797-1806.
Ball LM, Bernardo ME, Roelofs H, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163(4):501-509.
Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12):1662-1669.
Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579-1586.
Uccelli A, Morando S, Bonanno S, Bonanni I, Leonardi A, Mancardi G. Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? Curr Stem Cell Res Ther. 2011;6(1):69-72.
Sundin M, Örvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 2006;37(11):1051-1059.
Forslöw U, Blennow O, LeBlanc K, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2012;89(3):220-227.
Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22(3):593-599.
Remberger M, Ringdén O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol. 2012;96(6):822-824.
von Bahr L, Sundberg B, Lönnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. 2012;18(4):557-564.
Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294-1301.
Heo JS, Choi Y, Kim H-S, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115-125.
Liu Z, Wu X, Wang S, et al. Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia. Therap Adv Hematol. 2020;11:2040620720965411.
Wei G, Lin M, Cai Z, Huang H. Cytomegalovirus infection in mesenchymal stem cells and their activation could be enhanced by nuclear factor-κB inhibitor pyrrolidinedithiocarbamate in vitro. Transplant Proc. 2011;43:1944-1949.
Malaguarnera L, Pilastro MR, Vicari L, et al. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-κB activity. Cancer Invest. 2005;23(5):404-412.
Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012;3:274.
Moore DK, Loxton AG. Regulatory B lymphocytes: development and modulation of the host immune response during disease. Immunotherapy. 2019;11(8):691-704.
Wortel C, Heidt S. Regulatory B cells: phenotype, function and role in transplantation. Transpl Immunol. 2017;41:1-9.
van der Maas NG, Berghuis D, van der Burg M, Lankester AC. B cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children. Front Immunol. 2019;10:782.
Scroggins SM, Olivier AK, Meyerholz DK, Schlueter AJ. Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. PLoS One. 2013;8(9):e75158.
Zhang Q, Fujino M, Iwasaki S, et al. Generation and characterization of regulatory dendritic cells derived from murine induced pluripotent stem cells. Sci Rep. 2014;4(1):1-8.
Dalloul AH. B-cell-mediated strategies to fight chronic allograft rejection. Front Immunol. 2013;4:444.